1. Short Summary German-Austrian ART Guidelines 2017
The full version of the German-Austrian ART Guidelines 2017 is accessible under:
This file may be used for educational purposes, as long as content and attrition are left unchanged and a reference to the current guideline version is made. Any use for economic purposes requires prior approval of the authors

2. German-Austrian ART Guidelines 2017
Recommendations for treatment initiation were graded as follows:
Grading
Explanation
To be initiated
Treatment is clearly indicated
Should be initiated
Treatment is indicated, but deferral is justifiable
May be initiated
Treatment is an option
Should not be initiated
Treatment is not indicated
Recommendations regarding choice of drugs were graded as follows:
Grading
Explanation
Recommended
Preferred drug / combination
Alternative
May be given, may be the best choice for some patients
Not recommended
Only for special cases, but remains an option
Not indicated
Is not an option

3. German-Austrian ART Guidelines 2017
Start of treatment
Symptoms
CD4+
T cell count
ART
HIV-associated symptoms and diseases (CDC: C, B), HIVAN1, HAND2, and pregnancy3
Any value
To be initiated
Asymptomatic patients
(CDC: A)
< 500/µl
> 500/µl
Should be initiated
Acute retroviral syndrome with prolonged / severe symptoms
Asymptomatic/ mild symptoms during seroconversion
1. HIVAN: HIV-associated nephropathy; 2. HAND: HIV-associated neurocognitive disorder, 2. See separate Guidelines for antiretroviral treatment during pregnancy (

4. German-Austrian ART Guidelines 2017
Combination Partners 1 r
Combination Partner 2
Integrase inhibitors
Recommended: Dolutegravir
Raltegravir
Elvitegravir/c*(+TAF/FTC)
NNRTI
Recommended : Rilpivirine4 (+TAF/FTC)
Protease inhibitors
Recommended : Darunavir/r# or Darunavir/c*
(+TAF/FTC)
Alternative: Atazanavir/r# or Atazanavir/c*
Nucleoside-/ Nucleotide combinations
Recommended:
TAF/FTC1
ABC/3TC2
Alternative:
TDF/FTC3
TDF + 3TC +
not during pregnancy, 2. only with neagative screening for HLA-B*5701; use with care in patients with HIV plasma viremia > copies/ml or high cardiovascular risk, 3. TDF = tenofovir disproxil fumarate, phosphate, maleate, or succinate, also in in single tablet regimens (TDF/FTC/RPV; TDF/FTC/EVG/c) 4. not if HIV-RNA >100,000 copies/mL (not licensed)
*/c: Cobicistat, #/r: Ritonavir; TAF = Tenofovir alafenamide, FTC = emtricitabine, ABC = abacavir, 3TC = lamivudine